Annemieke H van der Hout
Overview
Explore the profile of Annemieke H van der Hout including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
381
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davidson A, Michailidou K, Parsons M, Fortuno C, Bolla M, Wang Q, et al.
Am J Hum Genet
. 2024 Aug;
111(9):2059-2069.
PMID: 39096911
Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against pathogenicity for commonly used variant classification guidelines....
2.
Schreurs M, Schmidt M, Hollestelle A, Schaapveld M, van Asperen C, Ausems M, et al.
Genet Med
. 2024 Jun;
26(9):101171.
PMID: 38828701
Purpose: Female CHEK2 c.1100delC heterozygotes are eligible for additional breast surveillance because of an increased breast cancer risk. Increased risks for other cancers have been reported. We studied whether CHEK2...
3.
Lanjouw L, Bart J, Mourits M, Willems S, van der Hout A, Ter Elst A, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730634
Analyzing tumor pathogenic variants (TPVs) in epithelial tubal/ovarian cancers (EOCs) has become an essential part of the diagnostic workflow in many centers to guide treatment options and genetic cascade testing....
4.
Lanjouw L, Mourits M, Bart J, Ter Elst A, Berger L, van der Hout A, et al.
Int J Gynecol Cancer
. 2023 May;
33(8):1260-1269.
PMID: 37137525
Background: Since 2015, Dutch guidelines have recommended pathogenic variant testing for all patients with epithelial ovarian cancer. Recently, recommendations shifted from germline testing to the tumor-first approach, in which tumor...
5.
Giardiello D, Hooning M, Hauptmann M, Keeman R, Heemskerk-Gerritsen B, Becher H, et al.
Breast Cancer Res
. 2022 Nov;
24(1):82.
PMID: 36419099
No abstract available.
6.
Giardiello D, Hooning M, Hauptmann M, Keeman R, Heemskerk-Gerritsen B, Becher H, et al.
Breast Cancer Res
. 2022 Oct;
24(1):69.
PMID: 36271417
Background: Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by...
7.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Mar;
30(5):630-631.
PMID: 35314806
No abstract available.
8.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Jan;
30(3):349-362.
PMID: 35027648
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance...
9.
Elsink K, Huibers M, Hollink I, van der Veken L, Ernst R, Simons A, et al.
Eur J Hum Genet
. 2020 Aug;
29(1):20-28.
PMID: 32733070
Dutch genome diagnostic centers (GDC) use next-generation sequencing (NGS)-based diagnostic applications for the diagnosis of primary immunodeficiencies (PIDs). The interpretation of genetic variants in many PIDs is complicated because of...
10.
Chau C, van Doorn R, van Poppelen N, van der Stoep N, Mensenkamp A, Sijmons R, et al.
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31382694
Germline pathogenic variants in the BRCA1-associated protein-1 () gene cause the BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327). BAP1-TPDS is associated with an increased risk of developing uveal melanoma (UM), cutaneous...